Explore innovative treatments for relapsed follicular lymphoma, focusing on novel therapies that enhance patient outcomes and ...
Zacks Investment Research on MSN
INCY's phase III Monjuvi study meets key goals in first-line lymphoma
Incyte INCY announced positive top-line results from a late-stage lymphoma study of Monjuvi/Minjuvi (tafasitamab), a ...
A positive top-line readout from a phase 3 trial has emboldened Incyte to seek the FDA’s blessing for the company’s Monjuvi ...
Everyday Health on MSN
Who should be on your large B-cell lymphoma care team?
Having a well-rounded care team can make large B-cell lymphoma treatment easier. Learn how nurses, social workers, and other ...
Burkitt's lymphoma is a rare and aggressive blood cancer characterized by a translocation of the MYC gene. It occurs most ...
Researchers at the Johns Hopkins Kimmel Cancer Center's Ludwig Center developed a new treatment that selectively targets ...
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for ...
Dr Kami Maddocks reflects on fresh data, such as the new epcoritamab combo approval, evolving CD19 sequencing data, and ...
Satyen K. Bordoloi My first memory of cancer is the younger brother of a classmate. Blood cancer, we whispered between ...
Fred Hutch researchers pioneered bone marrow transplantation, one of the most significant advances in treating lymphoma, leukemia and other blood cancers. We continue to improve bone marrow and blood ...
Based on phase 3 trial data, the FDA accepted an sBLA for nivolumab plus AVD for untreated stage III or IV classical Hodgkin lymphoma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback